A5007560050- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Economic and Financial Impacts of Cancer
- Advanced Breast Cancer Therapies
- Chemotherapy-induced cardiotoxicity and mitigation
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Gastric Cancer Management and Outcomes
- Ovarian cancer diagnosis and treatment
- Colorectal and Anal Carcinomas
- Colorectal Cancer Screening and Detection
- DNA Repair Mechanisms
- Lung Cancer Treatments and Mutations
- Health Systems, Economic Evaluations, Quality of Life
- Viral-associated cancers and disorders
- Helicobacter pylori-related gastroenterology studies
- Renal cell carcinoma treatment
- Lymphoma Diagnosis and Treatment
- Chemotherapy-related skin toxicity
- Inflammatory mediators and NSAID effects
AstraZeneca (United States)
2013-2023
AstraZeneca (Japan)
2015-2022
AstraZeneca (United Kingdom)
2004-2016
NorthShore University HealthSystem
1984-2010
Northwestern University
1985-2007
Evanston Hospital
1985-2007
American Society of Clinical Oncology
2001-2006
Loyola University Medical Center
2006
Kellogg's (Canada)
2006
Northern Indiana Cancer Research Consortium
2005
Patients with a germline BRCA1 or BRCA2 mutation make up small subgroup of those metastatic pancreatic cancer. The poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population.
To update the recommendations for use of tumor marker tests in prevention, screening, treatment, and surveillance gastrointestinal cancers.For 2006 update, an committee composed members from full Panel was formed to complete review analysis data published since 1999. Computerized literature searches Medline Cochrane Collaboration Library were performed. The Update Committee's focused attention on available systematic reviews meta-analyses studies.For colorectal cancer, it is recommended that...
To update the 1997 clinical practice guidelines for use of tumor marker tests in prevention, screening, treatment, and surveillance breast colorectal cancers. These are intended care patients outside trials.Six markers cancer eight were considered. They could be recommended or not routine special circumstances. In addition to carcinoembryonic antigen (CEA) CA 15-3, 27.29 was also considered among serum cancer.In general, significant health outcomes identified making (overall survival,...
The endogenous defenses of the mouse heart against reactive oxygen metabolites were investigated. activities three enzymes capable detoxifying activated determined in both and liver; cardiac muscle contains 150 times less catalase nearly four superoxide dismutase than liver. Glutathione peroxidase were, however, similar to two tissues. Assay glutathione after 6 wk selenium depletion with hydrogen peroxide cumene hydroperoxide as substrates revealed a >80% drop enzyme activity gave no...
Purpose Vascular endothelial growth factor (VEGF) plays a key role in the biology and prognosis of pancreatic cancer. Inhibitors VEGF suppress cancer preclinical models. The objectives this phase II study were to assess response rate overall survival patients who received gemcitabine with recombinant humanized anti-VEGF monoclonal antibody bevacizumab. Patients Methods previously untreated advanced 1,000 mg/m 2 intravenously over 30 minutes on days 1, 8, 15 every 28 days. Bevacizumab, 10...
The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall (OS) other secondary end points.
To determine the quality of life (QoL) women participating in Arimidex, Tamoxifen, Alone or Combination (ATAC) Adjuvant Breast Cancer Trial during first 2 years treatment.A total 1,021 were enrolled onto QoL subprotocol. All had completed primary treatment (surgery +/- radiotherapy chemotherapy) and to receive 5 adjuvant with anastrozole (n = 335), tamoxifen 347), a combination 339) both. Patients Functional Assessment Therapy-Breast (FACT-B) plus endocrine subscale (ES) at baseline 3, 6,...
This study was undertaken to investigate the effect of exogenous sulfhydryl compound administration on toxicity doxorubicin in mice. Pretreatment CDF1 mice with a pharmacologic dose (2,000 mg/kg) n-acetyl-l-cysteine 1 h before (20 mg/kg, i.p.) decreased lethality from 100% (n = 44) 37.7% 53), P less than 0.001. Variation timing and n-acetylcysteine significantly diminished its protective activity. also reduced long-term mortality animals receiving multiple doses doxorubicin; 10 wk after...
378 Background: POLO is the first phase 3 trial to evaluate maintenance therapy with poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib (O) in patients metastatic pancreatic cancer (mPaC) and a germline BRCA mutation ( gBRCAm) whose disease had not progressed on first-line platinum-based chemotherapy (PBC). demonstrated that significantly longer progression-free survival (PFS; primary endpoint) O than placebo (P; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.35–0.82; p=...
Abstract Background. Effective new agents for patients with colorectal cancer (CRC) disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor in CRC and inefficient tumor DNA repair mechanisms, such as those high-level microsatellite instability (MSI-H), would result synthetic lethality. Methods. This was an open-label phase II trial testing olaparib 400 mg p.o. b.i.d. disseminated, measurable failing therapies centrally...
Germline BRCA1 and/or BRCA2 mutations (gBRCAms) are risk factors for pancreatic cancer. The extent to which demographic and geographic affect the uptake of gBRCAm testing in cancer (PC) is unknown.We conducted a retrospective, descriptive analysis demographic/geographic data from first 2,206 patients with metastatic PC (mPC) screened eligibility enter phase III POLO trial maintenance olaparib. No formal statistical tests were performed.Of 2,167 previously unknown status, 128 (5.9%) had newly...
Results from the completed treatment analysis of ATAC (Arimidex, Tamoxifen alone or in combination) trial indicated that anastrozole was significantly superior to tamoxifen terms efficacy and safety adjuvant postmenopausal women with hormone receptor-positive (HR+) early breast cancer. On basis these results, this study estimated cost-effectiveness vs tamoxifen, perspective UK National Health Service (NHS). A Markov model developed using 5-year (ISRCTN18233230), as well data obtained...
4608 Background: The ras oncogene is mutated in about 90% of PC, leading to constitutive activation the Ras-Raf-MAPK signal transduction pathway. Sorafenib an inhibitor B-raf, VEGFR2, and PDGFR-B, has vitro activity against PC cell lines dependent on mutant Ras activation, anti-tumor xenograft models. In a phase I trial SG, 57% patients (pts) had stable disease (SD) (Siu, 2003). Methods: We conducted multi-center II SG advanced pts who had: no prior chemotherapy for metastatic disease, PS...
Four of 13 patients receiving intermittent high-dose methotrexate therapy experienced recurrent symptoms ocular irritation (burning, pruritus, "dry eyes") two to seven days after chemotherapy. Ophthalmic examination was unremarkable in symptomatic individuals except for decreased reflex production tears some patients. Pharmacokinetic studies a group these revealed concentrations equivalent those plasma at 24 and 48 hours treatment; reached 1 × 10−5 M during the infusion methotrexate. The...